Top Insider Buys and Sells Disclosed for Monday: Meta, CrowdStrike, GitLab and More
Corporate insider transactions can offer investors a useful glimpse into how executives, directors and major shareholders are managing their investments. The latest roundup of US insider trading disclosures published on September 29, 2026, highlighted notable purchases in companies including Inhibrx Biosciences, Angel Oak Mortgage REIT and Infinity Natural Resources, alongside substantial share sales involving Meta Platforms, CrowdStrike and GitLab.
These transactions deserve attention because insiders often have detailed knowledge of their companies' operations, financial position and strategic priorities. However, a purchase does not automatically mean a stock is undervalued, and a sale does not necessarily indicate that an executive expects the share price to fall.
The more useful approach is to examine the size of each transaction, the insider's role, the purchase or sale price, the reason for the transaction where disclosed, and the company's broader financial outlook.
Top Insider Buys: Which Stocks Attracted Executive Purchases?
The reported transactions covered several industries, including financial services, biotechnology and natural resources. Some executives purchased shares after their companies' stocks had weakened, while others increased their holdings through multiple transactions.
$290,510 purchase
Director and 10% owner Michael Fierman acquired 38,726 shares on September 25 at a weighted-average price of $7.5017 per share. His direct holdings increased to 105,247 shares following the transaction.
The purchase is notable because it was made when the stock was trading near its reported 52-week low. Buying after a decline can indicate that an insider sees value, but investors should also examine the company's mortgage-related risks, funding costs, asset quality and dividend sustainability.
$998,783 in purchases
CEO and director Mark Lappe purchased shares through multiple transactions on September 25 and September 28, according to the reported SEC Form 4 disclosures. The transactions included purchases at weighted-average prices ranging from approximately $98.88 to $101.70 per share.
CEO buying can attract attention because it represents a direct investment in the company by its chief executive. Nevertheless, biotechnology stocks can be particularly risky because their prospects may depend on clinical results, regulatory decisions, financing needs and commercial execution.
$299,993 in purchases
Executive Vice President and CFO Cary D. Baetz acquired 22,316 Class A common shares across transactions on September 24 and 25. Reported purchase prices ranged from $13.441 to $13.58 per share.
The purchases may signal confidence in the business, but investors should assess the company's production outlook, operating costs, commodity-price exposure and balance sheet before drawing conclusions about its shares.
$252,875 purchase
President, CEO and director Jennifer Jarrett purchased 12,500 ordinary shares on September 25 at a weighted-average price of $20.23 per share. The report described the purchases as open-market transactions funded personally.
This is another example of an executive committing personal capital to company shares. The long-term significance will depend on the company's business progress and the risks associated with its therapeutic development.
$383,900 purchase
CEO and director Christopher J. Abate purchased 100,000 shares on September 15 at $3.839 per share. The reported transaction also included grants of deferred stock units.
Although the purchase was earlier than several other transactions in the roundup, its size makes it noteworthy. Investors should evaluate Redwood Trust's mortgage investment portfolio, financing conditions, credit exposure and distribution policy rather than relying on the CEO's purchase alone.
Top Insider Sells: Meta, CrowdStrike and GitLab
Large insider sales frequently attract attention, particularly when a company's share price has risen substantially. But investors need to distinguish between discretionary selling and transactions arranged under a pre-established trading plan.
Approximately $21.36 million reported
Transactions associated with CEO Mark Zuckerberg involved the sale of 17,140 Class A shares through CZI Holdings, an entity for which he serves as trustee. The reported sales took place on September 24 under a Rule 10b5-1 trading plan adopted in January 2026.
What it means: The pre-arranged nature of the transactions is important context. The sales should not automatically be interpreted as a negative view of Meta's future performance.
Approximately $5.16 million sold
CEO George Kurtz sold 20,000 Class A shares across transactions on September 24 and 25 at prices ranging from $252.15 to $263.24. The reported sales were executed under a trading plan adopted in January 2026.
What it means: The transactions occurred when the stock was trading near its reported 52-week high. Still, scheduled selling can reflect diversification or personal financial planning rather than concerns about the cybersecurity business.
Approximately $101.09 million sold
Director Sytse Sijbrandij disposed of 2,116,100 Class A shares across several transactions between September 24 and 28. Reported prices ranged from $44.83 to $49.12. The sales were executed under a Rule 10b5-1 plan established in June 2026.
What it means: The size of the disposal makes it one of the most significant transactions in the roundup. However, investors should investigate the insider's remaining holdings, the plan's terms and the company's financial outlook before treating the sale as a bearish signal.
Approximately $4.25 million sold
CEO Luis von Ahn sold shares on September 16 at reported prices ranging from $150.17 to $151.54. The transactions were conducted under a Rule 10b5-1 plan. The report also described a separate acquisition resulting from the conversion of Class B shares into Class A shares.
What it means: Share conversions and scheduled sales need to be analysed separately. A change in share class is not necessarily a new open-market purchase, and the reported sale alone does not establish a change in management's outlook.
How Investors Should Interpret Insider Trading Disclosures
Insider transactions are useful because they reveal actual changes in ownership by people connected to a company. However, the information is most valuable when combined with financial statements, valuation measures and business developments.
Three principles can help investors avoid misleading conclusions.
Open-market buying deserves context. When a director or executive uses personal funds to purchase shares in the open market, the transaction may signal confidence. The signal becomes more informative when multiple insiders buy independently and the company's fundamentals support the decision.
Insider selling is not automatically bearish. Executives often receive stock-based compensation and may sell shares to diversify their wealth, meet tax obligations or fund personal expenses. Rule 10b5-1 plans allow qualifying insiders to arrange trades in advance under specified conditions.
Transaction size matters, but so does ownership after the trade. A large sale may look alarming in isolation. Its significance changes if the seller retains a substantial holding or the disposal represents only a small part of their total exposure.
Investors should also verify the original SEC Form 4 filing. Secondary reports can contain errors or omit important details, and the date a transaction is disclosed may differ from the date it occurred.
What Could These Insider Trades Mean for the Market?
The reported purchases and sales do not point to a single, uniform market outlook. Insider buying appeared across financial services, biotechnology and natural resources, while notable sales involved technology and software companies.
That mixed picture reinforces why insider trading data should be used as a research tool rather than a standalone trading signal. The transactions do not establish that the broader market is about to rise or fall.
For Indian investors following US stocks, the same principles apply when evaluating Form 4 filings. Focus on who traded, how the trade was structured, whether it was planned in advance, and how the transaction fits the company's fundamentals. For Indian-listed companies, promoter and management disclosures under SEBI regulations serve a related monitoring purpose, although the reporting requirements differ.
Conclusion
The latest reported insider activity highlighted substantial purchases by executives at Inhibrx Biosciences and Infinity Natural Resources, along with significant sales involving GitLab, Meta and CrowdStrike. The key takeaway is not that one group of stocks must rise or fall, but that ownership changes can provide useful clues when examined alongside financial performance, valuation and the reasons for each transaction.
Follow our blog for more insider trading updates, US stock news and global market analysis.
Disclaimer: This article is for informational and educational purposes only and should not be considered investment advice.